What are Amsterdam criteria?
Amsterdam criteria are a set of instructions used by general practitioners to determine whether the family is endangered by hereditary non -whitepasis of colorectal carcinoma (HNPCC), also known as Lynch syndrome. These instructions were originally developed in 1990 in Amsterdam and were revised in 1999 in the light of new information about genetics. The second set of criteria is sometimes referred to as Amsterdam II to distinguish them from earlier recommendations. Genetic advisors and other medical experts may consider them to assess a family with a history of colorectal and related cancer. This was later revised to include related cancer, such as growth in the small intestine, kidney pelvis and endometrium. Cancer must be confirmed by evaluation in the pathological laboratory and doctors must also exclude Condition called familial adenomatous polyposis, which can cause growth in the intestines.
In addition must cancer forEquenut two or more generations and at least one of them had to be diagnosed up to 50 years. The history that meets these instructions may indicate that a person could develop HNPCC, which could indicate the need for more aggressive screening and earlier interventions. Amsterdam criteria create a useful guide to doctors who decide on the recommendations for screening and treatment for their patients. After one person in the family meets the instructions, others may also want to consider the evaluation.
In the further modification of the original Amsterdam criteria, some experts say that two occurrences of cancer in a small family should qualify the patient to assess. Genetic conditions may be harder to identify and monitor in a small family because there are fewer people in which they can manifest; Several random cases of cancer in these cases may not be so random in close evaluation, as they could indicate that the family has a genetic predisposition to cancer. Patients undergoing review whether they meetAmsterdam criteria should also discuss other cancer and genetic problems, as this can be important.
Doctors can also use Bethesda instructions that work somewhat differently, to evaluate the patient at the risk of HNPCC and to determine whether tumors should undergo special testing. These instructions can be used to determine whether the patient should undergo genetic testing to check the risks of cancer. They can also provide information on whether more aggressive time screening would be recommended to capture growth early.